Skip to main content

Table 3 Multivariate analysis of PFS and OS (A) – un-stratified, (B) – stratified by treatment line, including interaction of NLR and BDX008

From: Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

 

PFS

OS

P

HR (95% CI)

P

HR (95% CI)

A

 BDX008 (+ vs -)

0.031

0.51 (0.28–0.94)

0.009

0.42 (0.21–0.81)

 BRAF (MUT vs WT)

0.895

0.96 (0.50–1.85)

0.793

1.09 (0.56–2.14)

 Linea (> 2 vs 2)

0.016

2.35 (1.17–4.71)

0.008

3.01 (1.33–6.82)

 LDH (highb vs low)

0.027

2.26 (1.10–4.67)

0.011

2.60 (1.24–5.43)

 LDH (n/a vs lowb)

0.322

1.53 (0.66–3.56)

0.332

1.56 (0.63–3.86)

B

 BDX008 (+ vs -)

0.096

0.57 (0.29–1.11)

0.002

0.32 (0.15–0.66)

 NLR ≥5 vs < 5

0.183

1.57 (0.81–3.03)

0.592

1.20 (0.61–2.37)

 BDX008*NLR interaction

0.041

3.57 (1.06–12.03)

0.004

6.53 (1.82–23.45)

  1. aLine of anti-PD-1 therapy
  2. bHigh LDH > 2 ULN, Low LDH < 2 ULN